Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Marizomib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Marizomib||NPI-0052||Marizomib (NPI-0052) is an irreversible inhibitor of the 20S proteasome, which leads to cell cycle arrest and apoptosis in tumor cells (PMID: 16891470).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||malignant glioma||not applicable||Bevacizumab + Marizomib||Phase I||Actionable||In a Phase I trial, Marizomib (NPI-0052) and Avastin (bevacizumab) combination therapy resulted in complete target lesion response in 14% (5/36), partial response in 25% (9/36), and stable disease in 31% (11/36) of Avastin (bevacizumab)-naive patients with WHO grade IV malignant giloma (Neuro Oncol (2016) 18 (suppl 6): vi13.).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02330562||Phase I||Bevacizumab + Marizomib||Study of Marizomib With Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma||Active, not recruiting|